Metagenomi, Inc. (NASDAQ:MGX) Receives Consensus Recommendation of “Moderate Buy” from Brokerages

Metagenomi, Inc. (NASDAQ:MGX) has earned a consensus rating of “Moderate Buy” from the seven analysts that are currently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among analysts that have covered the stock in the last year is $16.67.

A number of research analysts recently weighed in on MGX shares. Chardan Capital reissued a “buy” rating and set a $15.00 price target on shares of Metagenomi in a research report on Wednesday, November 20th. HC Wainwright lifted their target price on shares of Metagenomi from $7.00 to $14.00 and gave the stock a “buy” rating in a research report on Tuesday, December 10th.

Metagenomi Price Performance

NASDAQ MGX opened at $3.62 on Monday. The business has a fifty day simple moving average of $2.67 and a 200 day simple moving average of $3.02. Metagenomi has a 12 month low of $1.61 and a 12 month high of $12.74.

Institutional Investors Weigh In On Metagenomi

Several large investors have recently modified their holdings of MGX. Geode Capital Management LLC increased its position in Metagenomi by 105.8% in the third quarter. Geode Capital Management LLC now owns 338,031 shares of the company’s stock worth $734,000 after buying an additional 173,796 shares during the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Metagenomi by 209.4% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 136,624 shares of the company’s stock worth $296,000 after acquiring an additional 92,468 shares during the period. Novo Holdings A S increased its holdings in Metagenomi by 3.5% in the 2nd quarter. Novo Holdings A S now owns 1,800,000 shares of the company’s stock worth $7,344,000 after acquiring an additional 60,825 shares during the last quarter. Verition Fund Management LLC bought a new stake in Metagenomi in the 3rd quarter valued at about $82,000. Finally, Green Alpha Advisors LLC purchased a new stake in Metagenomi during the third quarter valued at about $69,000.

Metagenomi Company Profile

Metagenomi, Inc, a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases.